YDO1.F · Madrigal Pharmaceuticals, Inc

-

Please sign in to comment on YDO1.F

1 Comment

Admin

4 years, 1 month ago

Madrigal Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 14.0% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Madrigal Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 113.1% to $-59M since the same quarter in the previous year.

Finally, its free cash flow fell by 342.6% to $-55M since the same quarter in the previous year.

Based on the above factors, Madrigal Pharmaceuticals, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	US5588681057

Target Price	171.82
Market Cap	6B
PE Ratio	None
Beta	-0.69
Dividend Yield	None

ABOUT

Madrigal Pharmaceuticals, Inc

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

YDO1.F · Madrigal Pharmaceuticals, Inc

-

Madrigal Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Madrigal Pharmaceuticals, Inc using a moving average strategy